Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Janssen-Cilag International N.V
Woman and Man
Between 65 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
CR100967 : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité et la tolérance de l’ibrutinib (PCI-32765), inhibiteur de la tyrosine kinase de Bruton (BTK), en association avec la bendamustine et le rituximab, chez des patients âgés ayant un lymphome à cellules du manteau nouvellement diagnostiqué. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’ibrutinib en association avec de la bendamustine et du rituximab, chez des patients âgés de 65 ans ou plus présentant un lymphom...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
,
Gériatrie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy
The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA in subjects with active RA who are refractory to an anti-TNF alpha agent.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, 37.5, 50 mg) Administered Every 2 weeks in Subjects with Schizophrenia
The primary objective of this study is to demonstrate that paliperidone palmitate and RISPERDALCONSTA have comparable efficacy. The safety and tolerability of paliperidone palmitate inmaintenance ther...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
LYM3002 : Essai de phase 3, randomisé, évaluant l’efficacité de deux schémas thérapeutiques, VcR-CAP ou R-CHOP comprenant rituximab, cyclophosphamide, doxorubicine, prednisone associés au bortézomib ou à la vincristine respectivement, chez des patients ayant un lymphome à cellules du manteau. [essai clos aux inclusions]
L’objectif de cet essai est de déterminer l’association thérapeutique la plus efficace parmi deux schémas, VcR-CAP ou R-CHOP, chez des patients ayant un lymphome à cellules du manteau nouvellement dia...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation
To demonstrate that dapoxetine (30 or 60 mg prn) can prolong intravaginal ejaculatory latency time (IELT) as measured by stopwatch when compared to placebo in men with PE during the 24-week treatment ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients with Schizophrenia
The primary objective of this study is to evaluate the efficacy of PP3M compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis Badanie służące ocenie leku Toreforant (JNJ-38518168) w leczeniu pacjentów z umiarkowaną do ciężkiej łuszczycą plackowatą”
To evaluate the efficacy of JNJ-38518168 in subjects with moderate to severe plaque-type psoriasis. To assess the safety and tolerability of JNJ-38518168 in subjects with moderate to severe plaque-ty...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiety in Healthy Subjects
To determine whether R317573, after multiple dosing over one week in healthy male or female subjects, reduces the intensity of anxiety symptoms induced by breathing air with 7.5% carbon dioxide (CO2) ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Study of JNJ-38518168 in Symptomatic Adult Participants with Uncontrolled, Persistent Asthma
The primary objective is to assess the efficacy (as measured by the change from baseline in prebronchodilator percent-predicted forced expiratory volume in 1 second [FEV1]) of JNJ-38518168 compared wi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 5 ans
A Study of Efficacy and Safety of Ustekinumab in Patients with Primary Biliary Cirrhosis (PBC) Who had an Inadequate Response to Ursodeoxycholic Acid
This is a Phase 2 study that is divided into 2 parts. Part 1 is an open-label, proof-of-concept study. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study eval...
Country
None
organs
None
Specialty
None
unknown
More information
1
2
3
4
5
6
7
8
9
10
Next